

Haematologica
HAEMATOL/2017/168617
Version 4

Long-term impact of joint bleeds in Von Willebrand Disease: a nested case-control study

Karin P.M. van Galen, Piet de Kleijn, Wouter Foppen, Jeroen Eikenboom, Karina Meijer, Roger E.G. Schutgens, Kathelijn Fischer, Marjon H. Cnossen, Joke de Meris, Karin Fijnvandraat, Johanna G. van der Bom, Britta A.P. Laros-van Gorkom, Frank W.G. Leebeek, and Evelien P. Mauser-Bunschoten

Disclosures: Sources of financial support: This research was supported by an unrestricted grant from CLS Behring and the Dutch Hemophilia Foundation Disclaimer: not applicable Disclosure of Conflict of Interests: K.P.M. van Galen received research support from CSL Behring and Bayer for performing the Willebrand arthropathy study. F.W.G. Leebeek received research support from CSL Behring for performing the WiN-study, has received unrestricted research grants from Baxter for studies outside the submitted work, received a travel fee from Roche, and is a consultant for uniQure and Shire. J. Eikenboom received research support from CSL Behring and he has been a teacher on educational activities of Roche. E.P. Mauser-Bunschoten received unrestricted research/educational support from CSL Behring, Bayer, Baxter, LFB, Griffols, Novo Nordisk, Pfizer, Biovitrum and Sanquin. J.G. van der Bom has received unrestricted research/educational funding for various projects from the following companies: Bayer Schering Pharma, Baxter, CSL Behring, Novo Nordisk, and Pfizer. In addition, she has been a consultant to Baxter and Pfizer, and she has been a teacher on educational activities of Bayer Schering Pharma. M.H. Cnossen has received unrestricted research/educational funding for various projects and travel grants from the following companies: Bayer Schering Pharma, Shire, Novo Nordisk, Pfizer, CSL Behring and Novartis. K. Fijnvandraat is a member of the European Hemophilia Treatment and Standardization Board sponsored by Baxter, has received unrestricted research grants from CSL Behring and Bayer, and has given lectures at educational symposiums organized by Pfizer, Bayer and Baxter. K. Meijer received research support from Bayer, Baxter and Sanquin and was a member of the Dutch hemophilia advisory board of CSL Behring. B. Laros-van Gorkom has received unrestricted educational grants from Baxter and CSL Behring. R. Schutgens has received unrestricted research support from CSL Behring, Shire, Bayer, Novonordisk and Sanquin. K. Fischer received speaker's fees from Bayer, Baxter, CSL Behring, Biotest, Pfizer, NovoNordisk and Octapharma; performed consultancy for Bayer, Baxter, Biogen, CSL Behring, Freeline, NovoNordisk and Pfizer; and received research support from Bayer, Wyeth/Pfizer, Baxter, and Novo Nordisk. None of the other authors has a conflict of interest to declare.

Contributions: KG primary investigator: study design, writing protocol, data gathering, arranging additional financing, data analysis, wrote the manuscript PK involved in study design, performing research (conducting the HJHS) and commented on the manuscript WF performing research (conducting the X ray scores) and commented on the manuscript JE, KM, MC, JM, KF, JB, BL: WiN steering committee, involved in the study design, data analysis and commenting on the manuscript KF involved in the study design, study protocol, data analysis and commenting on the manuscript RS facilitating the research and arranging financing, comments on data analysis and on the manuscript FL supervising the whole study and head of the WiN studygroup EM original idea, arranging financing, supervising the whole study